In vivo Regenerative Technologies
We have a long history of studies pertinent to regeneration and repair in models of liver injury. More recently in collaboration with Dr. Kiani's lab at University of Pittsburgh we have contributed to the development of CRISPR based epigenetic tools that enable control over cell fate and function. We have applied these tools to control cell state in vitro and tissue response to injury in vivo.
1. CRISPR-Based Synthetic Transcription Factors In Vivo: The Future of Therapeutic Cellular Programming. Cell Systems. 2020 Jan 22;10(1):1-4.
2. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nature communications. 2019 Apr 23;10(1):1-0
3. Cas9 gRNA engineering for genome editing, activation and repression. Nat Methods. 2015 Nov;12(11):1051-4.
4 .CRISPR transcriptional repression devices and layered circuits in mammalian cells. Nat Methods. 2014 Jul;11(7):723-6.
5. Aag-initiated base excision repair promotes ischemia reperfusion injury in liver, brain, and kidney. Proc Natl Acad Sci U S A. 2014; 111:E4878-86